GW Link

Find Nonprofit and Small Business Grants

Advance Search

Only Available for Paid Subscribers
Clear Filters
Search Filters

Program to Accelerate Clinical Trials (PACT)

Grants to USA, Canada, and International Medical
Researchers for Clinical Studies of Alzheimer's Therapies

Agency Type:

Foundation / Corporation

Funding Source:

Add to My Calendar 

Alzheimer's Drug Discovery Foundation (ADDF)

LOI Date:


Deadline Date:

11/08/19 5:00 PM EST Receipt


Request a Grant Writer

Grants to USA, Canada, and International researchers, postdoctoral fellows, and clinicians based at nonprofit organizations, universities, academic medical centers, and biotechnology companies for clinical studies of therapies for Alzheimer’s and related dementias. Applicants must submit an LOI prior to submitting a full application.

The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer's disease and related dementias. The PACT RFP supports clinical trials, experimental medicine, and regulatory studies for novel drugs (small molecules and biologics including antibodies, peptides, gene therapies), repurposed drugs (existing drugs that are approved for other diseases and conditions), repositioned drugs (existing drugs that have entered clinical trials for other indications and have not yet been approved), and natural products.

Specifically, the PACT RFP supports:

Early-stage human clinical trials:

  • Phase 0 micro- or sub-therapeutic-dosing studies
  • Phase 1 single ascending dose and multiple ascending dose studies
  • Phase 2a biomarker-based proof-of-concept or proof-of-mechanism studies. These studies can validate novel molecular targets in humans and de-risk novel therapeutic approaches earlier in clinical development by assessing the potential efficacy of therapeutic interventions using pharmacodynamic outcomes

Regulatory studies:

  • Non-GLP and GLP pharmacology and toxicology studies, and scale-up, pre-formulation, and GMP manufacture required for investigational new drug (IND) and clinical trial authorization (CTA) preclinical packages. Funding is available for preparation of traditional and exploratory IND applications
  • Long-term toxicology studies to enable longer-term dosing in phase 2 trials, if not completed prior to phase 1 studies
  • GMP manufacture and testing of clinical grade drug required to move into phase 2 or phase 3 trials

Drug Targets - Current target areas of interest include, but are not limited to:

  • Neuroprotection
  • Inflammation
  • Vascular function
  • Mitochondria & metabolic function
  • Proteostasis
  • ApoE
  • Epigenetics
  • Synaptic activity and neurotransmitters
  • Other aging targets (e.g. senescent cells)

Other novel targets and pathways that are supported by compelling evidence demonstrating a rational biological connection to the disease process are encouraged.

For information on grant expectations, targets, and clinical trial design, see the URL for Full Text link below.

GrantWatch ID#:

GrantWatch ID#: 172502

Estimated Size of Grant:

Grants are up to $5 million based on stage and scope of research. Depending on the availability of funds, in certain cases, well-justified larger budgets may be considered.

Term of Contract:

Average grant duration varies (multi-year) with potential for follow-on funding.

Additional Eligibility Criteria:

Funding is open to researchers, clinicians, and postdoctoral fellows in the U.S. and worldwide working in:

- Academic medical centers and universities or nonprofits; Industry partnerships are strongly encouraged.
- Biotechnology companies; funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones. Existing companies and new startups are both eligible.

This RFP does not support anti-amyloid approaches (e.g., anti-amyloid aggregation, beta-amyloid vaccines, beta- or gamma-secretase inhibitors) and cholinesterase inhibitors.

Pre-Application Information:

Materials must be received by 5:00 PM EST on the deadline date.


-Letter of Intent: January 18, 2019
-Invited Full Proposal: February 8, 2019

-Letter of Intent: April 12, 2019
-Invited Full Proposal: May 10, 2019

-Letter of Intent: July 12, 2019
-Invited Full Proposal: August 9, 2019

-Letter of Intent: October 11, 2019
-Invited Full Proposal: November 8, 2019

For studies requiring additional support beyond ADDF funding, co-funding from other funding agencies or investors is encouraged.

For studies requiring additional support beyond ADDF funding, co-funding from other funding agencies or investors is encouraged.

Application Instructions:

Contact Information:

Before starting your grant application, please review the funding source's website listed below for updates/changes/addendums/conferences/LOIs.

Apply Online:

For program-related inquiries, please contact:

Alessio Travaglia, PhD, Scientific Program Officer

For application submission inquiries, please contact:

Grants and Mission-Related Investments Team

Alzheimer's Drug Discovery Foundation
57 West 57th Street, Suite 904
New York, NY 10019


URL for Full Text (RFP):

Geographic Focus:

USA: Alabama;   Alaska;   Arizona;   Arkansas;   California;   Colorado;   Connecticut;   Delaware;   Florida;   Georgia;   Hawaii;   Idaho;   Illinois;   Indiana;   Iowa;   Kansas;   Kentucky;   Louisiana;   Maine;   Maryland;   Massachusetts;   Michigan;   Minnesota;   Mississippi;   Missouri;   Montana;   Nebraska;   Nevada;   New Hampshire;   New Jersey;   New Mexico;   New York City;   New York;   North Carolina;   North Dakota;   Ohio;   Oklahoma;   Oregon;   Pennsylvania;   Rhode Island;   South Carolina;   South Dakota;   Tennessee;   Texas;   Utah;   Vermont;   Virginia;   Washington, DC;   Washington;   West Virginia;   Wisconsin;   Wyoming

USA Territories: American Samoa (USA)   Guam (USA)   Puerto Rico (USA)   Virgin Islands (USA)   Northern Mariana Islands (USA)

USA Compact Free Associations: The Federated States of Micronesia (USA)   Marshall Islands (USA)   Republic of Palau (USA)

Canada: Alberta   British Columbia   Manitoba   New Brunswick   Newfoundland and Labrador   Northwest Territories   Nova Scotia   Nunavut   Ontario   Prince Edward Island   Quebec   Saskatchewan   Yukon


International country outside of the USA, Israel and Canada.